Cervical myelography with Amipaque: seven years experience.
Amipaque (Metrizamide) when injected intrathecally, acts as a drug which may cause side effects and even complications. The adverse effects depend on the amount and concentration of the medium which reach the surface of the brain. The examination of the cervical area carries a risk that undiluted contrast material escapes into the cranial cavity. Knowledge of physical, physiological and pathophysiological properties of the medium is mandatory for proper management of the examination. Careful evaluation of the patient and the diagnostic problem and correct technique of cervical myelography gives perfect diagnostic information, minimal side-effects and no risk of serious complications.
D003287:Contrast Media / Q000009:adverse effects; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D008793:Metrizamide / Q000009:adverse effects; D009192:Myelography / Q000379:methods*; D009442:Neurilemmoma / Q000000981:diagnostic imaging; D010003:Osteoarthritis / Q000000981:diagnostic imaging; D012189:Retrospective Studies; D013120:Spinal Cord Neoplasms / Q000000981:diagnostic imaging; D013122:Spinal Diseases / Q000000981:diagnostic imaging; D013595:Syringomyelia / Q000000981:diagnostic imaging
D003287:Contrast Media; D008793:Metrizamide